menu
    • menu
    [{"orgOrder":0,"company":"Genetic Leap","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Genetic Leap","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genetic Leap \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genetic Leap \/ Eli Lilly"},{"orgOrder":0,"company":"Genetic Leap","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"GL-IL2-138","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genetic Leap","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Genetic Leap \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Genetic Leap \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Genetic Leap

    Menu

    Genetic Leap

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genetic Leap

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Genetic Leap

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GL-IL2-138

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genetic Leap receives FDA IND clearance for first-in-class, oral natural IL-2 modulator

                            Details : GL-IL2-138 is a small molecule RNA agent that modulates natural IL-2, allowing for downregulating or upregulating the immune system to fight devastating diseases.

                            Product Name : GL-IL2-138

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 16, 2025

                            Lead Product(s) : GL-IL2-138

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genetic Leap

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Genetic Leap

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genetic Leap, Lilly Collaborate to Advance Genetic Medicine Development with AI

                            Details : The collaboration will leverage Genetic Leap's RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $409.0 million

                            May 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth